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lecture fees from Eli Lihis study sought to evaluate the impact of treatment with prasugrel and high-dose clopidogrel on the basis of
platelet function testing in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary
intervention (PCI).Background The clinical impact of treatment with prasugrel in patients with ACS who have high platelet reactivity (HPR) is
unknown.Methods Patients with ACS who were pre-treated with clopidogrel and undergoing successful PCI were enrolled in a single-
center, prospective registry. Platelet function was measured 12 to 36 h after PCI with the Multiplate device (Roche
Diagnostics GmbH, Mannheim, Germany). Patients with HPR (>46 U) were switched to prasugrel or treated with
high-dose clopidogrel, and those without HPR continued treatment with 75 mg of clopidogrel.Results A total of 741 consecutive patients were enrolled in the study between September 2011 and August 2012, and
219 of these patients (29.5%) had HPR. Although platelet reactivity decreased after treatment adjustments in those
with HPR, prasugrel provided signiﬁcantly more potent platelet inhibition compared with high-dose clopidogrel
(p < 0.0001). Compared with patients without HPR, the risk of all-cause death, myocardial infarction, stent
thrombosis, or stroke at 1 year was signiﬁcantly higher in the high-dose clopidogrel group (hazard ratio [HR]: 2.27;
95% conﬁdence interval [CI]: 1.45 to 3.55; p < 0.0001), and patients who were switched to prasugrel had similar
outcomes (HR: 0.90; 95% CI: 0.44 to 1.81; p ¼ 0.76). Bleeding Academic Research Consortium (BARC) type 3/5
bleeding was also more frequent in patients treated with high-dose clopidogrel (HR: 2.09; 95% CI: 1.05 to 4.17;
p ¼ 0.04) than in patients switched to prasugrel (HR: 0.45; 95% CI: 0.11 to 1.91; p ¼ 0.28). In a multivariate model,
HPR with high-dose clopidogrel, but not with prasugrel, was an independent predictor of the composite ischemic
endpoint (HR: 1.90; 95% CI: 1.17 to 3.08; p ¼ 0.01).Conclusions Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to
a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding
complications with high-dose clopidogrel. (J Am Coll Cardiol 2014;63:1061–70) ª 2014 by the American College
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(5,6), the higher risk of major
bleeding together with the higher
treatment costs limit their use in
routine practice.
Theoretically, platelet function
assays could be useful to measure
the level of platelet inhibition
and guide the choice of the opti-
mal P2Y12 inhibitor to reduce costs
and bleeding complications; how-
ever, all currently available large-
scale, randomized studies failed
to show clinical improvementswhen treatment modiﬁcations were implemented on the
basis of platelet function testing (7–9). Notably, most of
these studies used high-dose clopidogrel to overcome high
platelet reactivity (HPR) or included patients at low risk for
recurrent events, and there is a lack of evidence on the po-
tential clinical beneﬁts of switching patients with ACS who
have HPR to treatment with prasugrel. Our aim was to
evaluate the clinical and pharmacodynamic impact of using
prasugrel or high-dose clopidogrel on the basis of platelet
function testing in a consecutive, all-comer, single-center
registry of nonelderly patients (younger than 80 years of age)
with ACS after PCI.Methods
Patient selection. As of September 2011, Hungarian
health insurers have approved and provided reimbursement
for treatment with prasugrel in patients with ACS under-
going PCI who have either diabetes or acute myocardial
infarction, but only when assessment of platelet function
veriﬁes that the patient did not respond to treatment with
clopidogrel. This regulation practically acts as a prasugrel-
prescribing policy for all interventional centers because of the
high costs of unreimbursed prasugrel for patients.
Acknowledging the lack of evidence behind this approach,
we aimed to build a single-center registry in one of the large-
volume academic centers in Hungary (Heart Institute,
University of Pécs, Pécs, Hungary) to evaluate the clinical
impact of optimizing P2Y12 inhibition on the basis of
platelet function testing.
Starting on September 1, 2011, consecutive, high-risk
patients with ACS admitted for urgent coronary angiog-
raphy were enrolled in a prospective registry. All patients
with ACS who were pre-treated with clopidogrel were
eligible for enrollment if PCI was performed successfully
with stent implantation and there was no contraindication
to treatment with a P2Y12 inhibitor for 1 year. Pre-
treatment with clopidogrel was deﬁned as either a loading
dose of 600 mg before admission or long-term treatment for
more than 5 days with 75 mg/day. Exclusion criteria
included an indication for chronic oral anticoagulation, age
older than 80 years, lack of pre-treatment with clopidogrel,or administration of other P2Y12 inhibitors before or during
PCI. Importantly, ticagrelor was not available in Hungary
during enrollment in the registry. Because we aimed to re-
cruit a real-life, high-risk, all-comer population of patients
with ACS, patients with cardiogenic shock, in pulmonary
edema, or who had successful resuscitation were not
excluded. All patients received 60 to 80 IU/kg of unfrac-
tionated heparin for PCI, and tiroﬁban was given at the
discretion of the operator as a 25-mg/kg bolus followed by an
optional 6- to 12-h infusion. Patients gave informed consent
to comply with the antiplatelet strategy offered and to be
available for regular follow-ups and telephone checkups for
1 year after PCI.
Platelet function testing and choice of P2Y12 inhibitor
treatment. Platelet function testing was performed with
the Multiplate analyzer (Roche Diagnostics GmbH, Man-
nheim, Germany) 12 to 36 h after PCI. If tiroﬁban was
administered, assessment of platelet function was postponed
until 24 h after cessation of treatment. HPR was deﬁned
according to the consensus cutoff, which was an adenosine
diphosphate (ADP)-test level >46 U (10).
In patients without HPR (ADP-test 46 U), standard-
dose (75 mg/day), generic clopidogrel was continued after
PCI (no HPR group). In contrast, patients with HPR were
either switched to prasugrel (HPR þ prasugrel group) with a
loading dose of 60 mg followed by a maintenance dose of
10 mg/day or treated with adjusted, high-dose clopidogrel
(HPR þ clopidogrel group) as previously described and
proposed by Bonello et al. (11). Brieﬂy, patients were treated
with additional loading doses of 600 mg of clopidogrel up to
4 times on the basis of controlled Multiplate testing each
day to normalize platelet reactivity below the pre-deﬁned
cutoff of HPR. According to the achieved level of platelet
reactivity after the second loading dose, a maintenance dose
of 75 mg/day (no HPR) or 150 mg/day (HPR) was selected.
Patients were not randomly allocated to the prasugrel or
high-dose clopidogrel groups; the choice of treatment was
not inﬂuenced by strict local rules but was left to the
discretion of the 7 expert operators. Some operators favored
a switch to prasugrel, whereas others supported the use of
high-dose clopidogrel.
Clinical endpoints. The primary composite efﬁcacy
endpoint was all-cause mortality, stent thrombosis, nonfatal
myocardial infarction, or stroke at 1 year. Secondary analyses
were performed for each component of the primary
endpoint, and rates of target vessel revascularization were
also compared. The primary safety endpoint was the
occurrence of major bleeding events during 1 year.
All-cause mortality was traced from hospital records,
follow-up visits, and a national vital record database. The
causes of fatal events were uncertain in many cases, so car-
diovascular mortality was not calculated. Stent thrombosis
was deﬁned as deﬁnite or probable according to the Aca-
demic Research Consortium criteria. Nonfatal myocardial
infarction was deﬁned according to the universal deﬁnition,
including type 1, 4a, and 4b. Major bleeding was deﬁned
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(BARC) criteria, including type 3 and 5 in the analysis.
Statistical analysis. Prior data were only available for the
impact of treatment with high-dose clopidogrel in HPR, so
the sample size was calculated to show a clinically relevant
difference in all-cause death, myocardial infarction, stent
thrombosis, or stroke between the HPR þ clopidogrel and
the no HPR groups. On the basis of the results of a prior
registry (12), we estimated a 2-fold risk (relative risk [RR]:
2.00) in the primary endpoint between groups with an
estimated 1-year absolute risk of 12% for the no HPR group
(5,6). Assuming a 30% rate of HPR and an equal distri-
bution of patients with HPR treated with high-dose clopi-
dogrel or prasugrel, 605 patients were required to detect a
difference between the HPR þ clopidogrel and no HPR
groups with 80% power at a 2-sided alpha level of 0.05.
Together with the prasugrel group, 700 patients were
needed. Allowing for dropouts, we planned to enroll 750
patients in the registry.
Continuous variables with normal distribution are pre-
sented as mean  SD, whereas non-normally distributed
variables are presented as median and interquartile range.
Categorical variables are expressed as frequencies and per-
centages. Differences between the 2 groups were assessed
with the Fisher exact test for categorical variables. Unpaired
Student t tests were used for comparisons of normally
distributed continuous variables between 2 groups, whereas
non-normally distributed variables were compared using the
Mann-Whitney U test.
Time-to-event data were visualized by Kaplan-Meier
curves for each group. Event rates represent Kaplan-
Meier estimates. Patients with HPR were compared with
the no HPR group in Cox regression models. Unadjusted
hazard ratios (HRs) together with 95% conﬁdence intervals
(CIs) were determined for clinical endpoints in univariate
Cox proportional models, and then a multivariable Cox
proportional hazards model was used to determine inde-
pendent predictors of all-cause death, myocardial infarction,
stent thrombosis, or stroke at 1 year. Of the 31 different
baseline clinical, procedural, pharmacological, and labora-
tory values collected (Table 1) for all groups, variables with
a p value < 0.05 in univariate analyses were entered into
a forward stepwise Cox proportional model. To test for
overﬁtting, sensitivity analyses were performed by building
multivariate models with a predictor-event ratio of 1:10.
These models contained either the clinically most relevant
predictors or the strongest univariate predictors of the
primary endpoint. Lack of violation of the proportional
hazard assumption was checked by using log minus log
survival plots.Results
Patient characteristics. Between September 1, 2011 and
August 31, 2012, 1,519 patients with ACS were admitted
to the Heart Institute at the University of Pécs for urgentcoronary angiography. After coronary angiography, 976
patients underwent PCI with successful stenting. On the
basis of the inclusion criteria, 741 patients were enrolled in
the study (Fig. 1). Table 1 shows the baseline clinical,
procedural, laboratory, and treatment characteristics of the
recruited patients according to the treatment groups. In
general, the cohort comprised a very high-risk, all-comer,
consecutive cohort of patients with ACS; 85% had an acute
myocardial infarction, 48% had an stent thrombosis-
segment elevation myocardial infarction, and 4.5% had
cardiogenic shock (Online Table 1). Patients with HPR
were signiﬁcantly younger and had a higher incidence of
diabetes and stent thrombosis-segment elevation myocardial
infarction as well as more complex coronary disease, re-
ﬂected by a longer total stent length. In addition, platelet
count, leukocyte count, and high-sensitivity C-reactive
protein levels were signiﬁcantly higher in patients with
HPR compared with those without HPR (Online Table 1).
In contrast, patients with HPR who were treated with
prasugrel or high-dose clopidogrel had comparable baseline
characteristics except for greater use of statins and beta-
blockers in the prasugrel group (Table 1). No baseline
clinical variables were found to predict allocation to the
prasugrel group in patients with HPR; however, a trend was
found for different use of prasugrel among the 7 operators
(median prasugrel use: 44%; minimum: 18%; maximum:
56%; p ¼ 0.09).
Platelet function results. On the basis of the Multiplate
results after PCI, 219 patients (29.5%) had HPR
(Figs. 1 and 2A). The 522 patients (70.5%) with normal
platelet reactivity continued treatment with 75 mg/day of
generic clopidogrel for 1 year. Of the 219 patients with
HPR, 128 patients (58%) were treated with adjusted high-
dose clopidogrel and 91 patients (42%) were switched to
treatment with prasugrel (Fig. 1). In the high-dose clopi-
dogrel group, 100%, 24%, and 7% of patients required a
second, third, and fourth loading dose of 600 mg of clopi-
dogrel, respectively. At discharge, 20% of the patients were
being treated with 150 mg/day of clopidogrel and 76% were
being treated with 75 mg/day. Four percent of the patients
died before the maintenance dose could be established.
After PCI, there was no difference between the HPR þ
clopidogrel group and the prasugrel group in the level of
platelet reactivity (Fig. 2B). Although both prasugrel and
repeated loading doses of 600 mg of clopidogrel reduced
platelet reactivity from baseline (p < 0.0001 for both), a
single loading dose of 60 mg of prasugrel followed by
a maintenance dose of 10 mg/day provided signiﬁcantly
more potent platelet inhibition than the repeated boluses
of 600 mg of clopidogrel at discharge (p < 0.0001)
(Fig. 2B). Although platelet reactivity signiﬁcantly increased
with the 10-mg/day dose of prasugrel during the mainte-
nance phase (p < 0.0001), 86% of the prasugrel-treated
patients still remained below the cut point for HPR. In
contrast, the standard dose and the doubled maintenance
dose of clopidogrel were ineffective to maintain the level
Table 1 Baseline Characteristics of the Patient Population
HPR (n ¼ 219)
No HPR (n ¼ 522) p Valuey
Prasugrel
(n ¼ 91)
High-Dose Clopidogrel
(n ¼ 128) p Value*
Clinical characteristics
Age, yrs 59.3  9.5 61.8  11.5 0.09 62.9  10.9 <0.05
Male 52 (57.1) 84 (65.6) 0.21 347 (66.5) 0.27
Type 2 diabetes mellitus 33 (36.3) 35 (27.3) 0.18 125 (23.9) 0.05
Type 2 diabetes mellitus (insulin-treated) 12 (13.2) 13 (10.2) 0.53 39 (7.5) 0.09
Hypertension 64 (70.3) 94 (73.4) 0.65 372 (71.3) 0.86
Known dyslipidemia 21 (23.1) 25 (19.5) 0.61 128 (24.5) 0.34
Smoking 16 (17.6) 25 (19.5) 0.86 105 (20.1) 0.69
Prior PCI 12 (13.2) 20 (15.6) 0.70 52 (10.0) 0.08
Prior CABG 4 (4.4) 11 (8.6) 0.28 49 (9.4) 0.32
Prior MI 14 (15.4) 25 (19.5) 0.48 76 (14.6) 0.27
Admission characteristics
Troponin positive 81 (89.0) 111 (86.7) 0.68 434 (83.1) 0.15
STEMI 55 (60.4) 69 (53.9) 0.41 234 (44.8) <0.01
NSTEMI 26 (28.6) 42 (32.8) 0.55 200 (38.3) 0.07
Unstable angina 10 (11.0) 17 (13.3) 0.68 88 (16.9) 0.15
Cardiogenic shock 4 (4.4) 10 (7.8) 0.41 19 (3.6) 0.12
Loading dose of 600 mg of clopidogrel 88 (96.7) 124 (96.9) 1.00 494 (94.6) 0.26
Use of clopidogrel 5 days before PCI 3 (3.2) 4 (3.1) 28 (5.4)
PCI procedure
Bare-metal stent 60 (65.9) 100 (78.1) 0.06 389 (74.5) 0.71
Total stent length, mm 32 (24–56) 36 (23–60) 0.86 30 (18.8–48) 0.01
Stent count/patient 2 (1–2) 2 (1–3) 0.52 2 (1–2) 0.06
Laboratory ﬁndings 1 day after PCI
Hemoglobin, g/dl 13.6  1.6 13.5  1.9 0.91 13.5  1.7 0.45
Leukocyte count, g/l 11.4 (9.0–14.7) 12.2 (9.3–15.3) 0.25 10.5 (8.2–13.3) 0.0001
Platelet count, g/l 270 (232–331) 272 (232–318.5) 0.81 245 (208–290) <0.0001
Creatinine, mmol/l 71.5 (63–82.8) 76 (63–96) 0.29 78 (65–93) 0.19
eGFR, MDRD 90.3  26.3 87.1  35.0 0.48 86.7  31.1 0.47
High-sensitivity C-reactive protein, mg/l 6.2 (2.6–25.2) 6.4 (2.0–36.3) 0.77 3.8 (1.5–16.2) 0.0004
Discharge medication
Aspirin 90 (98.9) 127 (99.2) 1.00 519 (99.4) 0.64
ACE-I/ARB 70 (76.9) 98 (76.6) 1.00 405 (77.6) 0.85
Beta-blocker 77 (84.6) 92 (71.9) 0.03 402 (77.0) 1.00
Proton pump inhibitor 83 (91.2) 119 (93.0) 0.62 501 (96.0) <0.05
Statin 87 (95.6) 110 (85.9) 0.02 465 (89.1) 0.79
Values are mean  SD, n (%), or median (interquartile range). *Comparisons between patients with HPR treated with prasugrel and patients treated with high-dose clopidogrel. yComparisons between
patients with and without HPR.
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; eGFR ¼ estimated glomerular ﬁltration rate; HPR ¼ high platelet reactivity; MDRD ¼ Modiﬁcation of Diet in Renal
Disease; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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of clopidogrel, resulting in rebound platelet reactivity during
the chronic phase (p < 0.0001), with 51% of patients
returning to HPR (Fig. 2). Notably, there was no difference
between the effect of 75 mg/day and 150 mg/day of clopi-
dogrel in patients with HPR (p ¼ 0.42).
Clinical outcomes. During 1-year follow-up, all-cause
mortality was 8.1%. The rate of deﬁnite/probable stent
thrombosis was 2.8%, and 5.3% of patients had major
bleeding. When all patients in the HPR groups were pooled
and compared with the no HPR group, a signiﬁcant increase
in all-cause mortality or stent thrombosis was observed
(Fig. 3A, Online Table 2). Despite treatment adjustments,the risk of the primary composite endpoint increased 1.7-
fold in the HPR group compared with the no HPR group
(HR: 1.67; 95% CI: 1.11 to 2.51; p ¼ 0.015), whereas there
was no difference in major bleeding complications between
the groups (Fig. 3B).
When the high-dose clopidogrel group was compared
with patients without HPR, a signiﬁcantly higher risk of
thrombotic events was observed (Figs. 4A to 4C, Table 2).
The risk of all-cause death, nonfatal myocardial infarction,
stent thrombosis, or stroke was more than 2-fold higher in
the high-dose clopidogrel group than in the no HPR group
(HR: 2.27; 95% CI: 1.45 to 3.55; p < 0.0001). Notably,
BARC type 3 or 5 major bleeding was also signiﬁcantly
Figure 1 Flowchart of Patient Enrollment in the Registry
ACS ¼ acute coronary syndrome(s); ADP ¼ adenosine diphosphate; CABG ¼ coronary artery bypass grafting; GPI ¼ glycoprotein IIb/IIIa inhibitor; HPR ¼ high platelet reactivity;
OAC ¼ oral anticoagulation; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack.
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HPR who were switched to treatment with prasugrel had
rates of thrombotic complications that were similar to thoseFigure 2 Platelet Function Results Before and After P2Y12 Inhibitor
(A) A scatter plot of platelet reactivity with the Multiplate device in all 741 patients after pre
in platelet reactivity among 219 patients with HPR who either switched to treatment with p
abbreviations as in Figure 1.in the no HPR group without any difference in all-cause
death, myocardial infarction, stent thrombosis, or stroke
(HR: 0.90; 95% CI: 0.44 to 1.81; p ¼ 0.76) (Figs. 4A to 4C,Treatment Adjustments in Patients With ACS After PCI
-treatment with clopidogrel, before treatment modiﬁcation was initiated. (B) Changes
rasugrel or were treated with adjusted high-dose clopidogrel. LD = loading dose; other
Figure 3 Thrombotic and Bleeding Complications in Patients With and Without HPR
(A) All-cause death or ST. (B)Major bleeding. Of note, all patients with HPR are grouped together in these comparisons regardless of whether they were treated with prasugrel or
high-dose clopidogrel. HR ¼ hazard ratio; ST ¼ stent thrombosis; other abbreviations as in Figure 1.
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switching patients to treatment with prasugrel compared
with others without HPR (Fig. 4D).Figure 4 Impact of Prasugrel and High-Dose Clopidogrel on Thrombo
(A) All-cause death. (B) All-cause death, MI, ST, or stroke. (C) All-cause death or ST. (D
Kaplan-Meier estimates. HRs with 95% CIs were calculated in Cox proportional hazards m
Consortium; MI ¼ myocardial infarction; other abbreviations as in Figures 1 and 3.Patients in the high-dose clopidogrel group and the
prasugrel group were not randomized, so all baseline char-
acteristics were compared extensively (Table 1). Aftertic and Bleeding Events in Patients With HPR
) Major bleeding (BARC 3 or 5). Event rates at 1 year are shown for each group as
odels with the no HPR group as a reference. BARC ¼ Bleeding Academic Research
Table 2 Clinical Outcomes at 12 Months Stratiﬁed According to the P2Y12 Inhibitor Used in HPR
No HPR
(Reference)
(n ¼ 522)
HPR þ Prasugrel
(n ¼ 91) HR (95% CI)*, p Value
HPR þ High-Dose
Clopidogrel
(n ¼ 128) HR (95% CI)*, p Value
Efﬁcacy
All-cause death 33 (6.32) 6 (6.59) 1.04 (0.44–2.48), 0.94 21 (16.41) 2.77 (1.60–4.79), <0.0001
Deﬁnite or probable stent thrombosis 10 (1.92) 3 (3.30) 1.72 (0.47–6.25), 0.41 8 (6.25) 3.48 (1.37–8.83), 0.009
MI 27 (5.17) 3 (3.30) 0.63 (0.19–2.07), 0.44 12 (9.38) 2.02 (1.02–3.99), 0.04
Stroke 3 (0.57) 0 (0.00) N/A 1 (0.78) 1.52 (0.16–14.57), 0.72
TVR 95 (18.2) 20 (21.98) 1.02 (0.62–1.70), 0.93 22 (17.19) 1.22 (0.76–1.96), 0.40
All-cause death or stent thrombosis 36 (6.90) 7 (7.69) 1.12 (0.50–2.51), 0.79 24 (18.75) 2.94 (1.76–4.94), <0.0001
Death, MI, stent thrombosis, or stroke 57 (10.92) 9 (9.89) 0.90 (0.44–1.81), 0.76 29 (22.66) 2.27 (1.45–3.55), <0.0001
Safety
Major bleeding (BARC 3 or 5) 25 (4.79) 2 (2.20) 0.45 (0.11–1.91), 0.28 12 (9.38) 2.09 (1.05–4.17), 0.04
Values are n (%). *Cox regression analyses using the no HPR group as a reference.
BARC ¼ Bleeding Academic Research Consortium; CI ¼ conﬁdence interval; HR ¼ hazard ratio; N/A ¼ not available; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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stent(s), angiotensin-converting enzyme inhibitor/angio-
tensin receptor blocker use, beta-blocker use, statin use, and
creatinine level, there was still a 2.5-fold increased risk of the
primary composite endpoint in the high-dose clopidogrel
group versus the prasugrel group (HR: 2.53; 95% CI: 1.08
to 5.93; p < 0.03) (Online Table 3).
Because of the clinical differences between patients with
and without HPR, univariate and multivariate models
were generated to identify independent predictors of the
composite primary endpoint. Using univariate models,Table 3
Clinical, Procedural, and Pharmacological
Stent Thrombosis, or Stroke at 1 Year
Univariate Co
Hazard
HR (95% CI)
Cardiogenic shock 15.87 (9.95–25.32
Acute renal failure (stage 4/5) 7.45 (4.28–12.96
High-dose clopidogrel, if HPR 2.27 (1.45–3.55)
Prasugrel, if HPR* 0.90 (0.44–1.81)
Leukocyte count (per 10-G/l increase) 2.39 (1.70–3.35)
Type 2 diabetes mellitus (insulin-treated) 2.31 (1.35–3.95)
Prior MI 1.92 (1.21–3.06)
STEMI 1.79 (1.18–2.70)
Age (per 10-yr increase) 1.69 (1.38–2.06)
Type 2 diabetes mellitus 1.57 (1.03–2.39)
No. of stents used (per 1 increase) 1.44 (1.22–1.70)
Stent length (per 10-mm increase) 1.16 (1.08–1.25)
C-reactive protein (per 10-mg/l increase) 1.08 (1.05–1.11)
Creatinine (per 10-mol/l increase) 1.04 (1.03–1.06)
Unstable angina 0.22 (0.08–0.60)
Drug-eluting stent (vs. bare-metal stent) 0.35 (0.19–0.66)
ACE-I/ARB 0.39 (0.26–0.59)
Statin 0.60 (0.33–0.96)
Beta-blocker 0.62 (0.41–0.96)
eGFR (per 10-ml/min/1.73 m2 increase) 0.82 (0.77–0.88)
Hemoglobin (per 10-g/l increase) 0.86 (0.76–0.97)
*Nonsigniﬁcant variable included for demonstration.
Abbreviations as in Tables 1 and 2.20 baseline variables were identiﬁed that were signiﬁcantly
associated with all-cause death, myocardial infarction, stent
thrombosis, or stroke (Table 3). According to the multi-
variate model, HPR with high-dose clopidogrel remained a
signiﬁcant, independent predictor of the primary endpoint
(HR: 1.90; 95% CI: 1.17 to 3.08; p ¼ 0.01), whereas pa-
tients with HPR who were switched to treatment with
prasugrel had no increase in thrombotic events (Table 3).
When the impact of outcome events was tested on sub-
sequent mortality, both stent thrombosis and major bleeding
proved to be a strong and independent predictor of 1-yearPredictors of All-Cause Death, MI,
x Proportional
Model
Multivariate Cox Proportional
Hazard Model
p Value HR (95% CI) p Value
) <0.0001 9.49 (5.42–16.62) <0.0001
) <0.0001
<0.0001 1.90 (1.17–3.08) 0.01
0.76*
<0.0001
0.002
0.006 2.47 (1.46–4.19) 0.001
0.006
<0.0001 1.56 (1.25–1.94) <0.0001
0.04
<0.0001
<0.0001 1.13 (1.03–1.24) 0.01
<0.0001
<0.0001
0.003
0.001 0.38 (0.16–0.89) 0.03
<0.0001 0.45 (0.27–0.72) 0.001
0.03
0.03
<0.0001
0.01
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1068mortality (Online Table 4). Interestingly, patients with stent
thrombosis had a 6-fold higher risk of major bleeding (RR:
6.23; 95% CI: 2.93 to 13.25; p < 0.00001), and patients
with a major bleeding event had a 7-fold risk of stent
thrombosis (RR: 7.20; 95% CI: 2.96 to 17.54; p< 0.00001).
Discussion
The main ﬁndings of this single-center registry can be
summarized as follows. First, switching patients with HPR
to treatment with prasugrel resulted in quicker and more
potent P2Y12 inhibition than repeating high-dose boluses of
clopidogrel on the basis of platelet function testing. A lack
of HPR can be maintained with 10 mg/day of prasugrel
during long-term treatment, but a clear rebound in platelet
reactivity occurred with maintenance doses of clopidogrel.
Second, patients with ACS who had HPR and were treated
with high-dose clopidogrel had an elevated risk of throm-
botic events after PCI, whereas those who were switched to
treatment with prasugrel had event rates that were compa-
rable to those of patients without HPR. In addition, patients
treated with high-dose clopidogrel had a higher risk of major
bleeding complications. Third, in a multivariate model, use
of high-dose clopidogrel in patients with HPR was an in-
dependent predictor of all-cause mortality, myocardial
infarction, stent thrombosis, or stroke at 1 year, whereas
switching to treatment with prasugrel was not associated
with thrombotic events.
Prasugrel and ticagrelor provide more potent and more
predictable P2Y12 receptor inhibition than clopidogrel (1–4).
Two large-scale randomized studies conﬁrmed a reduction
in cardiovascular death, myocardial infarction, or stroke
among patients with ACS who were treated with novel
P2Y12 inhibitors as compared with clopidogrel (5,6). How-
ever, there were signiﬁcant increases in major bleeding
complications with both prasugrel and ticagrelor (5,6). In an
era in which clopidogrel has become generic, the high
treatment costs of novel P2Y12 inhibitors together with the
higher risk of bleeding limit their use in current practice.
A possible solution to these limitations might be to use
prasugrel or ticagrelor selectively, that is, to restrict their use in
patients with HPR on clopidogrel who are being treated with
clopidogrel while continuing to treat good responders with
generic clopidogrel. However, this strategy has never been
tested in a randomized setting in patients with ACS. The
only evidence we currently have from 2 randomized studies is
that the use of platelet function testing to treat patients with
high-dose clopidogrel who are at low-to-moderate risk for
mortality and have HPR does not improve outcomes (7,9).
However, frequent criticisms of these 2 studies are that they
completely (7) or predominantly (9) used high-dose clopi-
dogrel in patients with HPR and included patients at low risk
for thrombotic events. A lack of clinical effectiveness of high-
dose clopidogrel in patients with HPR was further supported
by the RECLOSE-2 ACS (REsponsiveness to CLOpidogrel
and Stent-related Events in Acute Coronary Syndromes)registry (12), establishing the concept that HPR may be a
marker of higher risk but not a modiﬁable risk factor (13).
However, no data are available on the clinical impact of
prasugrel or ticagrelor in patients with ACS who have HPR.
In this respect, the results of our single-center, non-
randomized ACS registry might be of interest for several
reasons. First, we recruited a real-life patient population of
all-comer, consecutive, high-risk patients with ACS,
similar to the populations enrolled in TRITON (Trial to
Assess Improvement in Therapeutic Outcomes by Opti-
mizing Platelet Inhibition with Prasugrel) (5), PLATO
(Study of PLATelet Inhibition and Patient Outcomes) (6),
and/or the RECLOSE-2 ACS registry but not like the
cohorts of prior platelet function studies (7–9). Compared
with an all-cause mortality of 2% in ARCTIC (Assessment
by a Double Randomization of a Conventional Antiplatelet
Strategy versus a Monitoring-guided Strategy for Drug-
Eluting Stent Implantation and of Treatment Interrup-
tion versus Continuation One Year after Stenting)
(9), <1% in GRAVITAS (Gauging Responsiveness with A
VerifyNow assay–Impact on Thrombosis And Safety) (7),
and 0% in TRIGGER PCI (Testing Platelet Reactivity In
Patients Undergoing Elective Stent Placement on Clopi-
dogrel to Guide Alternative Therapy With Prasugrel) (8),
we found an 8.1% all-cause mortality rate in our high-risk
cohort. These differences can help explain how almost
twice as many primary endpoint events occurred in a study
that was one-third the size of the entire GRAVITAS study
(95 vs. 50). Our results are also in line with the
RECLOSE-2 ACS registry (12), which showed a more
than 2-fold higher risk of all-cause death, myocardial
infarction, stent thrombosis, or stroke in patients with
HPR despite up-titration of the dose of clopidogrel. The
only large-scale randomized study to show a beneﬁt for
high-dose clopidogrel is the CURRENT (Clopidogrel and
Aspirin Optimal Dose Usage to Reduce Recurrent Events)
trial, which suggested a slight advantage in the subgroup of
patients with ACS undergoing PCI (14). However,
because the trial compared a loading dose of 300 and 600
mg of clopidogrel with and without use of a double
maintenance dose for 1 week, the results are not compa-
rable to our registry and to prior platelet function studies
and prevent any meaningful conclusion on dose escalations
of clopidogrel in patients receiving a loading dose of
600 mg (14).
On the basis of the discussed evidence, high-dose clopi-
dogrel seems to have an insufﬁcient clinical effect to over-
come the higher risk of events in patients with ACS who
have HPR (7,9,12). Therefore, our registry suggests that
switching patients to treatment with prasugrel might decrease
the risk of thrombotic events to a level similar to that of
patients without HPR (Fig. 4). Platelet function results
supported these ﬁndings at the pharmacodynamic level,
conﬁrming superior platelet inhibition by prasugrel (Fig. 2).
In a prior large-scale platelet function registry, Stone et al.
(15) found that HPR after PCI was an independent
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1069predictor of both stent thrombosis and major bleeding. In
addition, both stent thombosis and major bleeding were
independent predictors of mortality that associations were
also replicated in our cohort. On the basis of this bidirec-
tional association, they speculated that it will be impossible
to reduce mortality in patients with HPR using more potent
P2Y12 inhibitor strategies, because for every stent throm-
bosis prevented, 4 extra major bleeds will be caused (15).
Our results suggest that the impact of more potent P2Y12
inhibitor strategies on major bleeding and stent thrombosis
is more complex; the less potent clopidogrel reloading
approach caused not only more stent thrombosis but also
more major bleedings (Fig. 4). The lower rate of bleeding
with prasugrel might be somewhat surprising in light of the
results of TRITON (5); however, we administered prasugrel
selectively to patients with HPR instead of a general pop-
ulation as analyzed in the cited trial. Although the observed
differences in bleeding might be due to chance because of
the low number of events or might be attributed to a less
sensitive bleeding scale used during follow-up (BARC 3/5
instead of BARC 2), a recent Scandinavian registry also
found a lower rate of visible bleeding with prasugrel (16).
These results should not confute the higher risk of bleeding
with prasugrel in a general ACS population but suggest that
selected patients (such as those with HPR on clopidogrel)
might tolerate more potent P2Y12 inhibition without an
excess risk of bleeding.
Study limitations. First and most importantly, the pra-
sugrel and clopidogrel groups were not randomized.
Although this might decrease the validity of our compar-
isons, registries are important for collecting real-life data
on unselected patients. Although it was left to the
discretion of the operator whether to choose prasugrel or
high-dose clopidogrel, the 2 groups ended up with a very
balanced distribution (42% vs. 58%) and most baseline
variables were well matched between the 2 groups
(Table 1). In addition, we observed similar results when
adjusting for possible confounders between the HPR
groups (Online Table 3). Furthermore, high-dose clopi-
dogrel in patients with HPR prevailed as an independent
predictor of the primary endpoint, corroborating the clin-
ical relevance of our observations (Table 3). Second, it is
unknown how these ﬁndings are transferable to ticagrelor
because the drug was not available during the enrollment
period in Hungary. Third, we only collected data on
BARC type 3/5 major bleeding events, and the difference
in major and minor bleeding complications remains un-
known. Although BARC type 3/5 major bleeding was
signiﬁcantly associated with all-cause mortality (Online
Table 4) and was a reliable marker of safety in
TRITON (5), it might also have been a reason for a lower
risk of bleeding among the prasugrel-treated patients.
Finally, our results cannot be extrapolated to elderly pa-
tients (older than 80 years of age) who might require dose
reduction with prasugrel but were generally excluded from
our registry.Conclusions
Treatment with prasugrel in patients with ACS who have
HPR is signiﬁcantly more effective than adjusted high-dose
clopidogrel both after loading doses and during the main-
tenance phase. In parallel to the pharmacodynamic ﬁndings,
treatment with prasugrel reduced thrombotic and bleeding
events to a level similar to that of patients without HPR,
whereas treatment with high-dose clopidogrel resulted in
a higher risk of both thrombotic and bleeding complications.
Further randomized studies are warranted to conﬁrm the
relevance of a platelet function-based selection of P2Y12
inhibitors in patients with ACS after PCI, but such studies
should avoid dose escalations of clopidogrel.
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